Nasdaq

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...
Opinion
Multiple Sclerosis News TodayOpinion

Living with MS migraines and navigating the ‘prior authorization’ trap

Columnist Desiree Lama finds herself having to argue that a medicine that she has been taking for migraines for years is still needed.
MarketWatch

Eli Lilly says FDA has approved new migraine drug Emgality

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...
Business Insider

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...
Healio

FDA approves Emgality for migraine prevention

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Emgality, a once-monthly, self-administered, subcutaneous injection, for the preventive ...
Healio

FDA grants headache drug priority review

Please provide your email address to receive an email when new articles are posted on . The FDA recently granted priority review to the supplemental Biologics License Application for Emgality ...
Nasdaq

Lilly's Emgality Gets FDA Approval for Cluster Headache

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.
FiercePharma

NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...
Business Insider

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
FiercePharma

Eli Lilly pins injectable migraine med Emgality against Biohaven's oral rival Nurtec ODT in head-to-head study

When the FDA awarded Biohaven Pharmaceuticals’ migraine med Nurtec ODT with a second indication last month, the company paraded the drug as the only option to both prevent and treat migraines. Now, ...
KRQE Blogs

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...